
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased […]












